ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: John Campbell, Nida Contracts Chief, New Head Of NCI Contracts Branch; PHS Honors Seven At NCI

June 10, 1983

FDA Moves to Regulate Lab-Developed Tests

August 1, 2014

Center Studies Prevention For Endometrial Cancer

February 25, 2005

Randomized Trials Discovered Roles For Newly Approved Nexavar and Sutent.

February 24, 2006

Obama Signs Cigarette Tax Increase Into Law

February 13, 2009

In Brief: Resolution wasn’t Strong Enough, Reizen Though; Two More chemicals reported Out of Bioassay

June 3, 1977